News

The experimental vaccine against SARS-CoV-2 that was the first to enter human trials in the United States has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics the infection-spreading part of the virus.

Responding to a need to quickly develop billions of doses of lifesaving COVID-19 vaccines, a scientific team at The University of Texas at Austin has successfully redesigned a key protein from the coronavirus, and the modification could enable much faster and more stable production of vaccines worldwide.

When the first COVID-19 vaccine trial in the U.S. began on March 16, history was being made. Never before had a potential vaccine been developed and produced for human trials so quickly—just 66 days since scientists published the genome sequence of the virus that causes the disease. This blindingly fast effort was only possible because a group of scientists and their partners in industry had already invested years in laying the groundwork.

The brain's primary immune cells play a fundamental role in alcohol use disorder, according to a new study from Scripps Research and The University of Texas at Austin. The scientists are the first to link these cells—known as microglia—to the molecular, cellular and behavioral changes that promote the increased drinking that's associated with alcohol dependence.

The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.

As terrifying as the current pandemic is, scientists believe some of the hundreds of other known coronaviruses in bats might also have the potential to make the cross-species leap into humans, as this one probably did. Scientists are already thinking about ways to prevent another coronavirus from spiraling out of control. Basic research published in the journal Science provides evidence that an antibody therapy that's effective against all SARS-like coronaviruses is possible.

University of Texas at Austin molecular biosciences assistant professor Xiaolu 'Lulu' Cambronne was one of 22 early career scientists selected to join the 2020 class of Pew Biomedical Scholars.

Two faculty members from the College of Natural Sciences have received distinguished Faculty Early Career Development (CAREER) Awards totaling $1,075,000 over 5 years from the National Science Foundation.

The country's first peer-reviewed study of a COVID-19 treatment that transfuses blood plasma from recovered patients into critically ill patients shows 19 out of 25 patients improving, including 11 discharged from the hospital.

Students at UT Austin already had plenty on their plates. When COVID-19 hit, the usual return from spring break and settling back into campus life turned instead into a mass migration—students scattering to shelter in place wherever they call home, in many cases moving back in with their families. Some became ill or began caring for sick family members. Classes moved online. Jobs ended. Everything was topsy turvy (it still is). But that hasn't stopped College of Natural Sciences undergraduates in public health, neuroscience and computer science from finding ways to help out their communities and fellow classmates.